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Abstract
Background Hepatitis C virus (HCV) is a risk factor for
chronic kidney disease (CKD) and end-stage renal disease
(ESRD). Direct-acting antiviral agents (DAAs) have
improved HCV management in CKD patients, however
real-world clinical practice data are limited.
Objective This study examined the prevalence of CKD
among HCV patients receiving oral DAAs in a real-world
setting. Comorbidities, early discontinuation rates, and
healthcare costs were compared between patients with and
without CKD.
Methods Patients with HCV who were treated with oral
DAAs between November 2013 and June 2015, and who
were enrolled in a US health plan, were identified. Early
discontinuation was calculated based on observed versus
expected treatment duration, and expected treatment
duration was based on genotype, initial treatment regimen,
baseline cirrhosis, and prior treatments. Healthcare costs
were calculated during the baseline, treatment, and post-
treatment periods.
Results This study included 3438 patients receiving oral
DAAs, of whom 6.9% had a CKD diagnosis. CKD patients
were more often male (70.8 vs. 62.9%, p = 0.02) and older
(mean age 62.0 vs. 58.8 years, p\ 0.001) than non-CKD
patients, and had a higher prevalence of most
comorbidities. Among early discontinuers, CKD patients
were more likely to experience anemia (19.4 vs. 7.7%,
p = 0.028).
Conclusions Few patients with CKD receive DAA treat-
ment for HCV infections. HCV patients with CKD had
significantly more comorbidities and higher baseline
healthcare costs than patients without CKD. Compared
with non-CKD patients, CKD patients were equally likely
to discontinue DAA treatment early but had higher rates of
anemia. This study highlights the need for more renal-
friendly HCV therapies.
Key Points
Data from observational studies are necessary to
bridge the gap between investigation and real-world
practice regarding the use of direct-acting antiviral
agents (DAAs) and the characteristics and
comorbidities of patients prescribed these agents.
Few hepatitis C virus (HCV) patients with chronic
kidney disease (CKD) [6.9%] received DAA
treatment for HCV infections.
Patients with CKD had more comorbidities and
higher baseline healthcare costs than patients without
CKD.
While HCV/CKD patients were equally likely to
discontinue treatment early compared with non-CKD
patients, they experienced significantly higher rates
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Hepatitis C virus (HCV) is a known risk factor for chronic
kidney disease (CKD) and end-stage renal disease (ESRD)
[1–4]. HCV is thought to trigger an immune cascade that
attacks the kidneys, resulting in glomerulonephritis, and is
also associated with insulin resistance and dyslipidemia
[5]. In patients with HCV, other comorbidities, such as
diabetes, hyperlipidemia, and cirrhosis, as well as male sex
and age\50 years, increase the risk of developing CKD
[2]. HCV infection in patients with CKD is associated with
renal disease progression, and those with more severe CKD
have a higher rate of positive anti-HCV antibodies [4].
HCV also increases the risk of developing ESRD, with a
5-year cumulative incidence rate of 52.6% compared with
38.4% in those without HCV [3]. In a study of patients with
CKD, HCV infection was associated with decreased kidney
function, a progressive loss of kidney function, and a
higher mortality risk [6]. While survival of stage 1 and 2
CKD patients infected with HCV matches those without
CKD [7], HCV in hemodialysis patients resulted in 1.35
times higher all-cause mortality and 3.82 times higher liver
disease-related mortality than those without HCV [8]. HCV
infection in CKD patients is also associated with increased
healthcare costs and utilization, with further increases in
those with ESRD [9].
Patients receiving hemodialysis are at a higher risk for
HCV infection, with a prevalence estimate of 8% (based on
HCV antibodies) in the US [10]. In dialysis patients,
breaches in infection control practices can result in patient-
to-patient transmission of HCV [11]; however, the majority
of infections are a result of nosocomial transmission (e.g.
contaminated multidose medication vials) [12, 13]. Preva-
lence of HCV in those receiving dialysis has been found to
increase with longer hemodialysis duration, male sex,
Black ethnicity, concurrent illness (e.g. diabetes, hepatitis
B), prior kidney transplant, and alcohol or drug abuse [14].
The goal of HCV treatment is sustained virologic
response (SVR), which is associated with reduced mortal-
ity and a reduced risk of cirrhosis and hepatocellular car-
cinoma [15, 16]. In patients awaiting renal transplants,
HCV treatment slowed the development of liver disease
and reduced the risk of HCV-related post-transplant com-
plications such as diabetes [17] and chronic allograft
nephropathy [18]. Treated transplant recipients also have
lower rates of glomerulonephritis compared with those who
are untreated [19]. The benefits of treatment may extend
beyond the liver, with improvements in both cardiovascular
and renal outcomes noted in one study of HCV-infected
diabetes patients [20].
Historically, treatment of CKD patients with HCV has
been pegylated interferon plus ribavirin [21]. In patients
with compromised renal function, this regimen is associ-
ated with low rates of SVR and early discontinuation due to
treatment-related side effects [22]. CKD patients often
suffer from multiple comorbidities, making them poor
candidates for pegylated interferon therapy. Additionally,
pegylated interferon is contraindicated following kidney
transplantation due to higher graft rejection rates [23, 24].
Consequently, few advanced CKD patients receive treat-
ment for HCV. In fact, the Dialysis and Practice Patterns
Study (DOPPS) found that while 9.5% of dialysis patients
were positive for HCV antibodies, only 1% received
antiviral therapy [25]. These major limitations highlight the
need for interferon-free, renal-friendly, anti-HCV
treatments.
Oral direct-acting antiviral agents (DAAs) were intro-
duced in 2011 and have improved the management of HCV
in patients with intact kidney function. Sofosbuvir/ledi-
pasvir, sofosbuvir/simeprevir, and ombitasvir/paritaprevir/
ritonavir plus dasabuvir have been FDA-approved since
2015 for genotype 1 HCV infections, while vel-
patasvir/sofosbuvir was recently approved in 2016. These
agents have increased SVR rates to [90% and require
shorter treatment durations, all with fewer side effects
compared with pegylated interferon plus ribavirin [26];
however, few studies have been conducted demonstrating
the safety and efficacy of DAAs in patients with CKD. One
phase III clinical trial in the severe renal impairment
population showed that 99% (n = 115/116) of HCV-in-
fected patients with stage 4–5 CKD treated with grazo-
previr/elbasvir achieved SVR and had a low rate of adverse
events [27]. Similarly, of patients with stage 4 CKD taking
a ombitasvir/paritaprevir/ritonavir regimen, 90% (n = 18/
20) experienced SVR, with no reported discontinuations
due to treatment side effects [28].
While no large-scale studies have been conducted on
sofosbuvir-containing regimens in patients with advanced
stage CKD, case series of patients treated with sofosbuvir/
simeprevir have shown SVR rates of 89% (n = 8/9) [29]
and 100% (n = 17/17) [30]. In the HCV-TARGET study,
patients with varying baseline renal function were treated
with sofosbuvir-containing regimens [31]. SVR was 88%
(n = 15/17) for those with estimated glomerular filtration
rate (eGFR) \30 mL/min, and anemia, worsening renal
function, and severe adverse events were more frequent in
those with reduced kidney function than those with intact
function. Despite the promise these results show, physi-
cians still face challenges managing patients with HCV and
compromised renal function. Results from clinical trials do
not always match outcomes in real-world clinical practice.
Data from observational studies are necessary to bridge the
gap between investigation and real-world practice regard-
ing the use of DAAs and the characteristics and comor-
bidities of the patients prescribed them. This study aimed
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to estimate the prevalence of CKD among HCV patients
receiving oral DAAs in a real-world setting. Additionally,
comorbidities, early discontinuation rates, potential side
effects, and healthcare costs were compared between
patients with HCV infection with and without CKD treated
with all-oral DAAs.
2 Methods
2.1 Study Design and Data Source
This was a retrospective study using medical and pharmacy
claims data, enrollment information, and linked laboratory
results from two US administrative health plan databases—
the Optum Research Database (ORD) and the Impact
National Benchmark Database (Impact). The ORD
includes enrollment information, medical and pharmacy
claims, and linked laboratory test results for approximately
14 million enrollees in commercial plans and 3 million
enrollees in Medicare Advantage with Part D plans annu-
ally. The ORD is geographically diverse and representative
of the US commercially insured population. The Impact
database contains enrollment information, medical and
pharmacy claims, and linked laboratory test results for
approximately 29.2 million people from 2004 to the pre-
sent, collected from 16 different healthcare plans serving
members across nine census regions. Data extracted for
each patient spanned 1 November 2013 through 30 June
2015. Medical claims data included International Classifi-
cation of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) diagnosis and procedure codes, Healthcare
Common Procedure Coding System (HCPCS) codes, rev-
enue codes, and paid amounts (combined health plan plus
patient paid amounts). Pharmacy claims data included
National Drug Codes for filled prescriptions, days supplied,
quantity of drug supplied, and paid amounts. Linked out-
patient laboratory results were available for a subset of the
research database. All study data were accessed using
techniques compliant with the Health Insurance Portability
and Accountability Act.
2.2 Study Population
To be included in the study, patients were required to have
one or more pharmacy claims for a DAA from 1 November
2013 through 30 June 2015 (Fig. 1). The index date was
defined as the pharmacy claim for the most recent DAA
treatment regimen during the patient identification period.
Patients were required to have continuous enrollment with
medical and pharmacy coverage at least 12 months pre-
index (baseline period) through treatment discontinuation,
and be at least 18 years of age as of the index year. The
post-treatment period was initiated based on the run-out of
days’ supply of the last prescription fill. Patients with
interferon use during the treatment period were excluded
from the study. Patients were divided into two cohorts
based on whether or not they had a diagnosis of CKD.
2.3 Study Measures
2.3.1 Patient Characteristics
Age, sex, geographic location, health plan type (com-
mercial, Medicare Advantage with Part D prescription
coverage), length of pre-index period, and CKD stage
were reported as of the index date. HCV genotype and
subtype were captured for those with available labora-
tory results. If multiple genotypes were recorded, the last
genotype result measured during the study period was
used. The Quan–Charlson comorbidity score was calcu-
lated during the pre-index period. The presence of
clinically relevant conditions/events during the pre-index
period was identified based on ICD-9-CM diagnosis
(070.X for HCV and 585.X for CKD) and procedure
codes from pre-index medical claims. The oral DAA
regimen was determined by pharmacy and medical
claims and categorized as the presence/absence of any
medication and as counts of individual medications. The
following regimens were examined: sofosbuvir/simepre-
vir, sofosbuvir/simeprevir plus ribavirin, sofosbuvir plus
ribavirin, ledipasvir/sofosbuvir, ledipasvir/sofosbuvir
plus ribavirin, and ombitasvir/paritaprevir/ritonavir plus
dasabuvir ± ribavirin.
2.3.2 Early Discontinuation
Discontinuation was defined as a gap in therapy of
C30 days for the first gap and C14 days for subsequent
gaps. The date of discontinuation was defined by the run-
out of days’ supply of the last prescription filled prior to the
gap in therapy. Discontinuation was determined for each
treatment regimen; patients who received ombitasvir/pari-
taprevir/ritonavir plus dasabuvir were not included in the
analysis of early discontinuation due to the small sample
size. Patients were removed from analyses of treatment
discontinuation at the time they disenrolled from the health
plan.
Patients were considered to have discontinued early if
the observed treatment duration was shorter than the
expected treatment duration. The expected treatment
duration was based on 2015 Infectious Diseases Society of
America/American Association for the Study of Liver
Diseases (IDSA/AASLD) treatment guidelines accounting
for HCV genotype, HCV RNA level, treatment status
(naive or experienced for 1 or more years), and baseline
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cirrhosis diagnosis [32]. If genotype was unavailable,
expected duration was based on observed treatment dura-
tion, treatment regimen, cirrhosis diagnosis, and treatment
status (naive or experienced).
The observed treatment duration was calculated from
the sum of the total number of days with medication
supply for oral DAAs containing sofosbuvir until dis-
continuation. The date of treatment initiation for each
HCV antiviral medication taken during the treatment
episode was identified separately and overall for the
episode. Among patients who discontinued early,
potential side effects were identified in the 4 weeks prior
to treatment discontinuation. Potential side effects
included anemia, rash, gastrointestinal symptoms (diar-
rhea and nausea), headache, fatigue, and insomnia, and
were identified based on ICD-9-CM diagnosis and pro-
cedure codes from the medical claims.
2.3.3 Costs
Healthcare costs were calculated for the baseline, treat-
ment, and post-treatment periods and reported as per-pa-
tient-per-month (PPPM). All-cause healthcare costs were
calculated as total costs (sum of medical and pharmacy
costs) and medical costs (sum of ambulatory, emergency,
inpatient, and other medical costs); all costs were inflation-
adjusted to 2014 US dollars using the Medical care com-
ponent from the Consumer Price Index [33].
2.4 Statistical Analyses
All study variables were analyzed descriptively. Numbers
and percentages were provided for dichotomous and
polychotomous variables, while means, medians, and
standard deviations were provided for continuous
≥1 pharmacy claim for simeprevir,
sofosbuvir, ledipasvir/sofosbuvir, or
ombitasvir/paritaprevir/ritonavir + dasabuvir
beginning 01 Nov 2013 through 30 June
2015; ≥18 years old
(N=9,172)
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Fig. 1 Patient sample
identification. CKD chronic
kidney disease
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variables. Results were stratified by CKD status, where
available. Bivariate comparisons of pre-index characteris-
tics and outcome measures were provided by CKD status,
and appropriate tests (e.g. t test, Chi-square test) were used
based on the distribution of the measure. Generalized linear
models of total, medical, and pharmacy costs during the
treatment and post-treatment periods were conducted using
a gamma distribution with a log link, and adjusting for
baseline costs, observed treatment regimen and duration,
patient demographics (age category, sex, insurance type),
comorbidities (Quan–Charlson comorbidity score, cirrho-
sis, HIV, diabetes, cardiovascular disorder, hypertension,
hepatitis B, drug abuse, and liver transplant), and prior
HCV treatment.
3 Results
After inclusion and exclusion criteria were applied, the
final study sample represented 3438 patients receiving oral
DAAs. Approximately 54% of patients had at least
36 months of baseline follow-up. The prevalence of CKD
among HCV patients receiving oral DAAs was 6.9%
(n = 236) (Fig. 1). In those with known CKD stage, 18.3%
were categorized as stage 1 or 2, 52.7% were stage 3, and
29.0% were stage 4 or more advanced (Table 1). Com-
pared with HCV patients without CKD, HCV patients with
CKD were more often male (70.8 vs. 62.9%, p = 0.02) and
older (mean age 62.0 vs. 58.8 years, p\ 0.001). HCV/
CKD patients also had higher Quan–Charlson comorbidity
scores (6.4 vs. 3.7, p\ 0.001), with more frequent diag-
noses of anemia (50.0 vs. 17.0%, p\ 0.001), cardiovas-
cular disorder (39.4 vs. 14.2%, p\ 0.001), cirrhosis or
end-stage liver disease [ESLD] (66.5 vs. 50.4%,
p\ 0.001), chronic obstructive pulmonary disease
(COPD)/asthma (55.1 vs. 40.8%, p\ 0.001), hypertension
(93.6 vs. 63.7%, p\ 0.001), diabetes (61.9 vs. 23.4%,
p\ 0.001), liver transplant (29.7 vs. 4.7%, p\ 0.001),
fatigue (41.5 vs. 27.6%, p\ 0.001), gastrointestinal com-
plications (58.9 vs. 32.4%, p\ 0.001), heart failure/rheu-
matic heart disease (92.4 vs. 67.2%, p\ 0.001), hepatitis B
(14.0 vs. 7.0%, p\ 0.001), hepatocellular carcinoma (13.6
vs. 4.6%, p\ 0.001), depression (45.3 vs. 36.0%,
p\ 0.001), and drug abuse (26.3 vs. 20.1%, p = 0.030)
compared with their non-CKD counterparts. Patients were
most commonly treated with ledipasvir/sofosbuvir, sofos-
buvir ? simeprevir, and sofosbuvir ? ribavirin (Table 2),
with an average treatment length of 3.0 months for CKD
patients and 3.1 months for non-CKD patients.
Slightly more HCV patients with CKD discontinued
DAA treatment early compared with HCV-only patients;
however, the results were not statistically significant
(15.6% [n = 31/199] compared with 12.0% [n = 324/
2695], p = 0.140) (Table 3). Additionally, CKD stage did
not impact early discontinuation rates (17.7% in stage 1–3
vs. 8.3% in stage 4 ESRD, p = 0.133). While patients with
and without CKD were equally likely to discontinue early,
more patients with CKD had reported potential side effects.
Insomnia and gastrointestinal symptoms were most com-
monly reported overall (Table 4). Patients with CKD were
significantly more likely to experience anemia compared
with those without CKD (19.4 vs. 7.7%, p = 0.028), while
gastrointestinal symptoms (32.3 vs. 17.9%, p = 0.052) and
rash (22.6 vs. 11.1%, p = 0.062) trended towards
significance.
Total unadjusted PPPM healthcare costs in the baseline
period were higher in HCV/CKD patients than HCV-only
patients ($5481 vs. $1922, p\ 0.001), with medical costs
almost four times higher ($4286 vs. $1110, p\ 0.001) in
patients with CKD compared with those without (Table 1).
Total healthcare costs were also higher among HCV/CKD
patients than HCV-only patients during both the treatment
and post-treatment periods (average post-treatment follow-
up was 5.8 months in CKD patients and 5.3 months in non-
CKD patients). Compared with HCV-only patients,
patients with CKD experienced higher PPPM pharmacy
costs during the post-treatment period ($793 vs. $454,
p = 0.005), but experienced similar costs during the
treatment period ($39,988 vs. $38,773, p = 0.083), repre-
sentative of the cost of DAA therapy. Medical costs were
double in the treatment period ($2365 vs. $1069,
p\ 0.001) and four times higher in the post-treatment
period ($4087 vs. $958, p = 0.023) compared with patients
without CKD (Table 5). While total adjusted PPPM
healthcare costs in the post-treatment period were higher
among HCV/CKD patients than HCV-only patients ($2056
vs. $1526), the results were not statistically significant
(cost ratio = 1.35, p = 0.105) (Table 5). Significant pre-
dictors of higher costs were higher baseline costs, a
sofosbuvir ? simeprevir 12-week regimen (cost
ratio = 1.36, p = 0.012), all durations of sofosbu-
vir ? simeprevir ? ribavirin (cost ratio = 1.85,
p = 0.007), a sofosbuvir ? ribavirin 8-week regimen (cost
ratio = 2.214, p = 0.034), cirrhosis (cost ratio = 1.264,
p = 0.020), and HIV infection (cost ratio = 1.864,
p = 0.014), while prior HCV treatment was associated
with lower costs (cost ratio = 0.698, p\ 0.001) in the
post-treatment period (data not shown). Adjusted total
costs in the treatment period ($40,383 vs. $39,988, cost
ratio = 1.01, p = 0.352) were also not significantly dif-
ferent for HCV/CKD patients versus HCV-only patients
(Table 5). Higher baseline costs were significantly associ-
ated with higher total costs, as were HIV infection (cost
ratio = 1.031, p = 0.038) and diabetes (cost
ratio = 1.014, p = 0.025), while liver transplantation (cost
ratio = 0.976, p = 0.047) and prior HCV treatment (cost
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Table 1 Baseline patient demographics and clinical characteristics
Demographics Valid n HCV with CKD [n = 236] Valid n HCV-only [n = 3202] p value
Male sex 236 167 (70.76) 3202 2013 (62.87) 0.02
Age, years [mean (SD)] 236 61.96 (7.74) 3202 58.76 (9.50) \0.001
Geographic region 236 3202
Northeast 38 (16.10) 765 (23.89) 0.007
Midwest 52 (22.03) 589 (18.39) 0.166
South 117 (49.58) 1374 (42.91) 0.049
West 29 (12.29) 474 (14.80) 0.340
Insurance type 236 3202
Commercial 106 (44.92) 2018 (63.02) \0.001
Medicare Advantage 130 (55.08) 1184 (36.98) \0.001
Pre-index observation period, months 236 3202
C12 to\18 40 (16.95) 460 (14.37) 0.292
C18 to\24 23 (9.75) 340 (10.62) 0.743
C24 to\36 46 (19.49) 611 (19.08) 0.864
C36 127 (53.81) 1791 (55.93) 0.541
CKD stage 186 –
1 8 (4.30) – –
2 26 (13.98) – –
3 98 (52.69) – –
4 13 (6.99) – –
5 2 (1.08) – –
ESRD 39 (20.97) – –
Prior treatment status 236 3202
Treatment-experienced 64 (27.12) 780 (24.36) 0.342
Genotype 73 1141
1 56 (76.71) 895 (78.44) 0.162
2 10 (13.70) 172 (15.07) 0.453
3 7 (9.59) 65 (5.70 0.332
4 0 (0.00) 6 (0.53) 0.506
6 0 (0.00) 1 (0.09) 0.786
Multiple 0 (0.00) 2 (0.18) 0.701
Quan–Charlson comorbidity score [mean (SD)] 236 6.38 (2.47) 3202 3.67 (2.11) \0.001
Comorbidities 236 3202
Alcohol abuse 19 (8.05) 210 (6.56) 0.346
Anemia and treatment 118 (50.00) 543 (16.96) \0.001
Anxiety 88 (37.29) 1046 (32.67) 0.152
Cardiovascular disorder 93 (39.41) 456 (14.24) \0.001
Cirrhosis 106 (44.92) 1064 (33.23) \0.001
COPD/asthma 130 (55.08) 1307 (40.82) \0.001
Decompensated cirrhosis/ESLD 82 (34.75) 611 (19.08) \0.001
Depression 107 (45.34) 1151 (35.95) 0.005
Diabetes 146 (61.86) 748 (23.36) \0.001
Drug abuse 62 (26.27) 645 (20.14) 0.030
Fatigue 98 (41.53) 883 (27.58) \0.001
GI complications 139 (58.90) 1038 (32.42) \0.001
Heart failure/rheumatic heart disease 218 (92.37) 2153 (67.24) \0.001
Hepatitis B 33 (13.98) 223 (6.96) \0.001
Hepatocellular carcinoma 32 (13.56) 148 (4.62) \0.001
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ratio = 0.987, p = 0.038) were associated with lower total
costs during the treatment period (data not shown).
4 Discussion
This retrospective study evaluated patient characteristics,
discontinuation, and costs in CKD patients infected with
HCV and treated with oral DAAs. Our results provide
important insights into this difficult-to-treat population in a
real-world setting. A relatively low number of patients with
HCV and CKD were treated with oral DAAs. CKD patients
were older and sicker than their non-CKD counterparts,
with higher rates of cirrhosis and ESLD, anemia, cardio-
vascular disorder, fatigue, heart failure/rheumatic heart
disease, COPD/asthma, hypertension, diabetes, liver
transplant, hepatitis B, hepatocellular carcinoma, and
depression. While patients with and without CKD were
equally likely to discontinue treatment early, CKD patients
were more likely to experience potential side effects, par-
ticularly anemia and GI symptoms. Actual healthcare costs
during the treatment and post-treatment periods were
Table 1 continued
Demographics Valid n HCV with CKD [n = 236] Valid n HCV-only [n = 3202] p value
History of liver transplant 70 (29.66) 149 (4.65) \0.001
HIV 34 (14.41) 376 (11.74) 0.213
Hypertension 221 (93.64) 2041 (63.74) \0.001
Total baseline healthcare costs [mean (SD)] 236 5481.08 (12,651.96) 3202 1922.16 (3768.85) \0.001
Pharmacy costs 1195.40 (2222.60) 812.45 (2110.52) 0.007
Medical costs 4285.68 (12,359.18) 1109.71 (2850.60) \0.001
Data are expressed as n (%) unless otherwise specified
CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, ESLD end-stage liver disease, ESRD end-stage renal disease, GI
gastrointestinal, HCV hepatitis C virus, SD standard deviation
Table 2 Distribution of
treatment regimen among the
HCV-infected patients with
CKD and HCV-only cohorts
Treatment regimen HCV with CKD [n = 236] HCV-only [n = 3202]
Sofosbuvir/simeprevir 75 (31.78) 835 (26.08)
Sofosbuvir/simeprevir ? ribavirin 10 (4.24) 127 (3.97)
Sofosbuvir ? ribavirin 54 (22.88) 804 (25.11)
Ledipasvir/sofosbuvir 89 (37.71) 1394 (43.54)
Ledipasvir/sofosbuvir ? ribavirin 5 (2.12) 30 (0.94)
Ombitasvir/paritaprevir/ritonavir ? dasabuvir 3 (1.27) 12 (0.37)
Data are expressed as n (%)
CKD chronic kidney disease, HCV hepatitis C virus
Table 3 Adherence to expected treatment durationa,b
Total [n = 2894] HCV with CKD [n = 199] HCV-only [n = 2695] p value
Discontinued early 355 (12.27) 31 (15.58) 324 (12.02) 0.140
Completed as expected 2432 (84.04) 159 (79.90) 2273 (84.34) 0.099
Extended beyond expected 107 (3.70) 9 (4.52) 98 (3.64) 0.523
Data are expressed as n (%)
CKD chronic kidney disease, HCV hepatitis C virus
a Includes only those patients with known expected treatment duration
b Patients who received ombitasvir/paritaprevir/ritonavir were excluded from the analysis due to the small sample size
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significantly higher among CKD patients than non-CKD
patients; however, after adjustment for baseline costs, DAA
treatment regimen and duration, as well as patient char-
acteristics and comorbidities, costs during the treatment
and post-treatment periods were no longer different
between the cohorts.
During the study period (November 2013 to June 2015),
6.9% of CKD co-infected HCV patients were treated with
oral DAAs, which is lower than prevalence estimates
reported in previous studies. In a study in Taiwan, 16.5% of
study participants seropositive for HCV had CKD [1],
while a US study found the unadjusted prevalence of HCV
infection in patients receiving hemodialysis to be 14.4%
[14]. Similarly, a recent study of HCV patients reported
14.4% had stage 3–5 CKD [34]. Patients with more
advanced CKD have higher rates of HCV infection, with
one study reporting a prevalence of 8.5% in those with
stage 1 CKD and 14.5% in those with stages 4–5 [4]. Our




HCV with CKD [n = 31] HCV-only [n = 324] p value
Any potential side effect 17 (54.84) 149 (45.99) 0.345
Anemia 6 (19.35) 25 (7.72) 0.028
Rash 7 (22.58) 36 (11.11) 0.062
Gastrointestinal 10 (32.26) 58 (17.90) 0.052
Fatigue 1 (3.23) 27 (8.33) 0.313
Insomnia 11 (35.48) 72 (22.22) 0.096
Headache 0 (0.00) 9 (2.78) 0.347
Data are expressed as n (%)
CKD chronic kidney disease, DAA direct-acting antiviral, HCV hepatitis C virus
a Patients who received ombitasvir/paritaprevir/ritonavir were excluded from the analysis due to the small
sample size
Table 5 Unadjusted and adjusted PPPM treatment and post-treatment period healthcare costs (US$)












42,353 39,842 0.003 40,383 39,988 0.352
Medical costs 2365 1069 \0.001 1432 1112 0.228
Pharmacy costs 39,988 38,773 0.083 38,749 38,865 0.704
Total HCV-related
costs
39,775 38,668 0.134 38,650 38,751 0.784
Medical costs 647 403 0.201 504 378 0.260




4879 1412 0.012 2056 1526 0.105
Medical costs 4087 958 0.023 1488 1026 0.123




2356 279 0.107 438 280 0.171
Medical costs 2356 279 0.107 438 280 0.171
Pharmacy costs 0 0 – 0 0 –
CKD chronic kidney disease, HCV hepatitis C virus, PPPM per-patient-per-month
a 14.1% of individuals had zero post-treatment pharmacy costs. Adjusted costs were calculated using a two-part (logistic/gamma) model.
Expected costs were calculated at the individual level [Ppositive cost 9 predicted cost]. Adjusted costs are the mean of these expected costs
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study included patients with varying renal function, not just
those with advanced CKD, which may partially explain the
lower prevalence we observed. Additionally, our study
included only patients treated with oral DAAs, indicating
that a relatively low number of CKD patients infected with
HCV are treated with oral DAAs.
In this study, patients with CKD were slightly more
likely to discontinue treatment early than non-CKD
patients (15.6 vs. 12.0%); however, the results were not
significant. This is similar to findings from the HCV-
TARGET study, with slightly higher early discontinuation
rates in patients with eGFR \45 mL/min (4.1 vs. 2.5%,
p = nonsignificant) [31]. The early discontinuation rates
reported in this study are higher than those reported in
previous case series and clinical trial results. This is likely
a direct result of the definition based on AASLD guidelines
used to identify the expected treatment duration in the
claims data. Since early discontinuation was calculated
comparing the observed treatment duration with the
expected treatment duration, patients were categorized as
being an early discontinuer compared with guidelines.
While HCV patients with and without CKD were equally
likely to discontinue early, more patients with CKD were
anemic. In those who discontinued early, evidence of anemia
was observed in 19.4% of CKD patients and 7.7% of those
withoutCKD(p = 0.028).While not significant,CKDpatients
also more frequently experienced gastrointestinal symptoms
(32.3 vs. 17.9%, p = 0.052) and rash (22.6 vs. 11.1%,
p = 0.062) compared with non-CKD patients, which may be
clinically relevant. Similarly, the HCV-TARGET study also
foundhigher rates of treatment side effects amongpatientswith
renal insufficiency (eGFR\45 mL/min) than those with nor-
mal renal function (21.9 vs. 6.3%, p\0.001). Even after
removing regimenswith ribavirin, a higher rate of anemia (10.0
vs. 0.01%) and worsening renal function (20.0 vs. 0.01%) was
still found in those with an eGRF\45 mL/min [31]. Anemia,
as a result of decreased erythropoietin production, and nausea
are both known complications of CKD and it is unknown
whether they were caused by treatment with DAAs alone.
In this study, HCV patients with CKD had significantly
higher healthcare costs than patients without CKD ($5481
vs. $1922) following treatment with DAAs. These results
are similar to a recent study comparing costs in HCV
patients with and without ESRD CKD with costs in
patients without CKD in a commercially insured and
Medicare population [9]. Costs during the 1-year follow-up
period were significantly higher in commercially insured
patients with non-ESRD CKD ($3720) and ESRD ($8117)
compared with patients with no CKD ($1085). Patients
with Medicare Advantage insurance experienced a similar
pattern of costs.
Considering the incremental burden of CKD from HCV
along with hepatic and extrahepatic manifestations, more
renal-friendly treatment of HCV is imperative. Recently,
the 2016 AASLD guidelines recommended additional
DAA treatment options for patients with renal impairment,
including those with severe renal impairment and ESRD
[32]. These treatment options should take into considera-
tion the higher prevalence of critical comorbidities identi-
fied in this study that can impact adherence to treatment,
including adverse events while receiving treatment. These
additional comorbidities highlight the need to identify
CKD patients as a special population that may require
additional monitoring to achieve safe and effective HCV
treatment outcomes.
4.1 Limitations
Claims data offer the advantage of large sample sizes of
patients with diverse medical histories; however, certain
limitations inherent to claims-based analyses should be
considered when interpreting the results of this study. The
presence of a medical or pharmacy claim is not proof-
positive for the presence of disease or that the medication
was consumed or taken as prescribed. Cost estimates using
data aggregated from claims paid by a single health payer
may underestimate total direct healthcare expenditures for
patients with multiple payers (e.g. Medicare, managed care
beneficiaries) and do not include information relating to
non-medical costs associated with patient or societal
expenditures, such as transportation for treatment or missed
work days. Misclassification may exist because baseline
medical history information was limited to at least 1 year;
however, more than half of the patients had at least 3 years
of baseline follow-up. Treatment-naive status may be
misidentified as the definition relies on the absence of
evidence of prior treatments in the claims data, impacting
the determination of treatment duration. There are limita-
tions as to the generalizability of the results of this study in
that the study data are from a commercial and Medicare
Advantage population and may not be generalizable to
other populations. Lastly, our inability to detect deaths,
particularly in this advanced population, may have resulted
in misclassification of some patients as early discontinuers.
5 Conclusions
Standard treatment with pegylated interferon and ribavirin
is associated with a host of complications in patients with
renal impairment. The introduction of DAAs has provided
an interferon-free treatment option that has shown higher
rates of SVR with fewer potential side effects than inter-
feron therapy in clinical trial data for this population;
however, distinct recommendations in support of DAAs in
renal-insufficient patients did not exist. Patients with CKD
Direct-Acting Antivirals in HCV Patients with CKD
had more comorbidities and higher baseline healthcare
costs than patients without CKD. While HCV/CKD
patients were equally likely to discontinue DAA treatment
early compared with non-CKD patients, they experienced
significantly higher rates of anemia and slightly higher
rates of rash and gastrointestinal complications that may be
clinically relevant. This study highlights the need for more
renal-friendly HCV therapies.
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